Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature

Current first-line systemic treatment in most patients with metastatic hormone receptor-positive, HER-2 negative breast cancer is an aromatase inhibitor in combination with a cyclin dependant kinase (CDK) 4/6 inhibitor. Frequently, these patients require palliative radiotherapy (RT) for symptomatic...

Descripción completa

Detalles Bibliográficos
Autores principales: David, Steven, Ho, Gwo, Day, Daphne, Harris, Marion, Tan, Jennifer, Goel, Shom, Hanna, Gerard G., Srivastava, Ranjana, Kruss, Gill, McDowell, Lachlan, White, Michelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689545/
https://www.ncbi.nlm.nih.gov/pubmed/33227663
http://dx.doi.org/10.1016/j.tranon.2020.100939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689545/
https://www.ncbi.nlm.nih.gov/pubmed/33227663
http://dx.doi.org/10.1016/j.tranon.2020.100939

Ejemplares similares